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This study aims to evaluate a new Planned Adaptive® software (TomoTherapy Inc., Madison, 
WI) of the helical tomotherapy system by retrospective verification and adaptive re-planning 
of radiation treatment.  Four patients with different disease sites (brain, nasal cavity, lungs, 
prostate) were planned in duplicate using the diagnostic planning kVCT data set and MVCT 
studies of the first treatment fraction with the same optimization parameters for both plan 
types.  The dosimetric characteristics of minimum, maximum, and mean dose to the targets 
as well as to organs at risk were compared.  Both sets of plans were used for calculation of 
dose distributions in a water-equivalent phantom.  Corresponding measurements of these 
plans in phantom were carried out with the use of radiographic film and ion chamber.  In the 
case of the lung and prostate cancer patients, changes in dosimetric parameters compared 
to data generated with the kVCT study alone were less than 2%.  Certain changes for the 
nasal cavity and brain cancer patients were greater than 2%, but they were explained in part 
by anatomy changes that occurred during the time between kVCT and MVCT studies.  The 
Planned Adaptive software allows for adaptive radiotherapy planning using the MVCT stud-
ies obtained by the helical tomotherapy imaging system.
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Introduction
Helical tomotherapy (HT) (TomoTherapy Inc, Madison, WI) is a form of im-
age guided radiation therapy in which a linear accelerator is mounted on a slip 
ring gantry, similar to those used in helical CT scanners (1-6).  During radiation 
treatment, the patient is translated through the gantry while the beam continu-
ally rotates around the patient, providing helical delivery.  Using the same x-ray 
source, operated at 3.5 MV, megavoltage CT (MVCT) images can be acquired 
before, during, or after daily treatment of the patient (7, 8).  The MVCT ac-
quisition is currently used at our center for daily image registration with the 
planning kVCT (Brilliance Big Bore, Philips) dataset [see example in Fig. 1 
(a)] and, thus, allows accurate patient re-positioning prior to daily treatments. 
These MVCT studies also provide new and exciting opportunities for adaptive 
radiotherapy (ART) (9, 10) by verification of delivered dose and replanning of 
patients throughout their coarse of treatment.
The new Planned Adaptive® software (TomoTherapy Inc, Madison, WI) provides 
tools for both dose verification and ART using the daily MVCT images acquired 
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by helical tomotherapy system.  The MVCT study is always 
limited to a 40 cm circle of reconstruction due to the maxi-
mum tomotherapy collimator width whereas kVCT studies 
usually have a 50 cm circle of reconstruction (Brillaince Big 
Bore provides reliable CT numbers for up to 60 cm circle 
of reconstruction).  Also MVCT scans are typically shorter 
in craniocaudal direction to save time and reduce the imag-
ing dose.  In order to compensate for insuffient field-of-view 
of the MVCT studies and accurately calculate dose, Planned 
Adaptive inserts the 40 cm round MVCT images into the 
kVCT planning study by creating a merged MVCT/kVCT 
image set, hencefore called “hybrid image”, for convenience. 
Since kVCT studies are obtained with a slice thickness of 3 
mm, and MVCT scanning on tomotherapy has possible slice 
spacing of 6, 4, or 2 mm, interpolation within the MVCT is 
required in order for the slice thickness of the merged image 
to be a uniform 3 mm thickness.  A different image-value-
density table (IVDT) is also required for dose calculations 
performed using MVCT images due to the higher beam en-
ergy of the tomotherapy unit.
Previous studies have shown that significant tumor regres-
sion may occur throughout treatment (9, 11-14) and in some 
cases, organs at risk (OARs) may move into high dose re-
gions, thus delivering more dose than initially planned for 
critical tissue or underdosage of tumor volumes (11).  By 
adapting the plan to these changes, the OARs can be spared 
of this inadvertent high dose deposition (15).  Such adapta-
tion also provides opportunities to increase organ sparing 
beyond what was initially planned, or to escalate dose de-
livered to the tumor while maintaining the same conformal 
avoidance of OARs if there is significant tumor regression 
during treatment.  The question of using pre-treatment im-
ages for planning has been studied for another on-board im-
aging device, kV cone-beam CT, by Ding et al. (16, 17).
Clinically, Planned Adaptive provides unique opportunities 
for both dose verification and adaptive planning using the hy-
brid images already available.  Dose verification allows for 
dosimetric assessment of the effects of misalignment or anat-
omy changes, while adaptive planning, when used in conjunc-
tion with the verification doses, allows for the adaptation of 
plans if the deformation or regression is considered clinically 
significant.  However, the current software does not correct 
for the effects of anatomical deformation on dose delivered to 
individual tissue elements (18).
Previously an evaluation of the Planned Adaptive software 
has been done for phantom (19).  The purpose of this study 
is to assess quantitatively the accuracy of this software us-
ing hybrid images for cases from our clinical practice.  This 
was performed by retrospectively planning of four patients 
who had been treated on tomotherapy using both their ini-
tial kVCT and their first day MVCT studies, assuming no 
changes in patient anatomy occurred between these two stud-
ies.  Multi-fraction dose accumulation was not studied in this 
preliminary work.  The intent was to evaluate the possibility 
to employ hybrid images for dose delivery verification and 
adaptive therapy prior to their clinical usage.
Methods and Materials
Four patients with cancerous lesions at different sites (lung, 
prostate, nasal cavity, and brain) who had previously been 
treated at the London Regional Cancer Program using heli-
cal tomotherapy were selected retrospectively.  A new hy-
brid image based plan was generated employing the same 
dosimetric constraints used for the original HT plan.  This 
along with identical pitch, field width, modulation factor, and 
number of optimization iterations insures that the same plan-
ning procedure is implemented for both kVCT and hybrid 
image plans.  The plans were optimized using the beamlet 
dose computation option.
Using the actual MVCT study of the first treatment day of 
each patient, hybrid images were created using the Planned 
Adaptive software.  The number of scanned MVCT slices is 
defined by the minimum requirement of the PTV coverage. 
Radiation oncologist may require imaging of some easily 
identifiable anatomic feature or organ at risk.  In practice, it 
means around 20 MVCT slices with 6 mm interslice spac-
ing.  Verification doses were calculated for each patient and 
compared to the planned doses.  To accomplish this, Planned 
Adaptive applies the daily delivery sinogram (based on the 
original kVCT plan) in the calculation of the dose distribu-
tion on the current hybrid image.  In clinical practice, it is 
intended that after dose verification calculations, summation 
doses (taking into account previously delivered fractions to 
tissue elements) are generated.  Once a summation dose has 
been calculated, Planned Adaptive can allow for the modifi-
cation of structures (including the generation of avoidance or 
“top up” regions based on patterns of accumulated dose that 
may have resulted in over- or under-dosage), and the hybrid 
image set with modified structures are transferred to the to-
motherapy planning station for optimization of an “adaptive” 
plan to tailor the further treatments to correct for changes that 
have occurred up to that point in treatment.  Depending on the 
clinical scenario, additional verifications and adaptive plans 
can be generated to correct for further anatomy changes (i.e., 
continued weight loss or tumor regression, internal anatomy 
warping).  However, our current goal was not to test adap-
tive function as such but rather to see how close are the plan 
based on kVCT image with corresponding IVDT and the plan 
based on the hybrid image with IVDT for 3.5 MV beam.
In this study, we sought to verify that plan calculated on the 
hybrid image obtained with the first MVCT correlates well 
with the initial kVCT based plan.  MVCT of the first day of 
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treatment was chosen because we assumed that no signifi-
cant changes in anatomy occurred after kVCT scan and the 
contours for all structures were kept the same for kVCT and 
hybrid image based plans.  In doing so, one would have in-
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Figure 1:  Verification dose volume histograms calculated on first day MVCT study for (a) lung cancer patient, (b) nasal cavity cancer patient, (c) prostate 
cancer patient, and (d) brain cancer patient.  The solid lines are the DVH curves as planned, while the dashed lines are the verification DVH curves as calcu-
lated on the MVCT study.  Superposition of the two sets of curves indicates equivalency of verification dose and planned dose.
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Figure 2:  Hybrid image for the lung cancer patient with planned on 
kVCT study (solid lines) and calculated using hybrid image (dashed lines) 
isodose lines.
Air
Figure 3:  A slight deformation causes the minimum dose in PTV to be 
improperly calculated.
Figure 4:  kVCT/MVCT hybrid image of brain cancer patient with a part of 
the lens contoured outside of patient.
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creased confidence that adaptive plans generated later after 
multi-fraction radiation delivery, based on the hybrid image 
alone would be truly reflective of subsequent adapted delivery. 
Isodose contours and dose volume histogram (DVH) curves 
were used to quantify the differences between the plans.  Each 
hybrid image plan was directly compared to the kVCT plan in 
order to determine the effects of the inherent lower quality of 
MVCT images due to the higher beam energy.
To verify the calculation accuracy, delivery quality assur-
ance (DQA) procedures were performed for all patients as 
an independent verification of the plans.  Radiographic film 
and ion chamber point dose measurements with a cylindrical 
water equivalent “cheese” phantom were performed for both 
kVCT and hybrid image based plans.  In order to correct for 
any differences due to set-up or organ motion error (and in 
doing so isolate the effects of differences in the planning 
as opposed to the anatomy), the hybrid image for adaptive 
planning was corrected by the automated registration shifts 
used for the first day of treatment.
Results
Figure 1 shows the comparison of DVHs as planned (solid 
Technology in Cancer Research & Treatment, Volume 7, Number 6, December 2008
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lines) with those calculated with the “verification dose” op-
tion of the Planned Adaptive software for each of the pa-
tients by applying the kVCT generated fluence map to the 
first day hybrid image.
The results of kVCT vs. hybrid image based plans are pre-
sented in Tables I to IV where the maximum, minimum, me-
dian, and average dose for six selected structures were com-
pared for the lung, prostate, nasal cavity, and brain cancer 
patients.  A maximum of 2% difference between the plan us-
ing the merged image and the plan using the kVCT planning 
image for each parameter of the structures used for compari-
son was considered clinically acceptable.  Figure 2 shows 
a lung cancer patient isodose view illustrated on the hybrid 
image with kVCT study visible outside 40 cm MVCT circle. 
We observe good agreement between planned (on kVCT 
study) and calculated (using hybrid) image isodose lines for 
a delivery fraction.  DQA procedures of tomotherapy sys-
tem were also used for both kVCT and hybrid image plans. 
Point dose measurements provided quantitative comparison 
shown in Table V.  Film isodose contours exhibited good 
agreement for all plans, and most point dose measurements 
agreed within 2% with those predicted by the corresponding 
plan.  In certain cases, point dose measurement differences 
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exceeded 2% due to either the low delivered dose or the high 
dose gradient in this region.
Discussion
The verification dose of the nasal cavity patient (see Fig. 
1b), when compared to the planned dose, shows small dif-
ferences most notably for the optic chiasm, the planning tar-
get volume (PTV) and clinical target volume (CTV).  The 
fine structures, such as nasal cavities, on the MVCT images 
are blurred due to the lower image quality of the hybrid im-
age study.  The blurring results in changes of CT numbers 
in corresponding voxels, which may affect the dose calcula-
tion.  This effect likely accounts for the difference (clinically 
insignificant) in the optic chiasm DVH concordance.  In our 
case, MVCT images were acquired with coarse (6 mm) slice 
spacing.  In the future, we plan to study the effect of scan-
ning with smaller interslice distances on the image quality 
and how this improves verification dose calculations.  In this 
instance, interfaces between bone and air represent a high 
contrast situation, thus improvements through adjustment 
of slice thickness may improve the correspondence between 
plans.  In addition, small discrepancies in the registration 
that resulted in portions of the PTV residing in air (Fig. 3) 
help account for the discrepancy as they result in a calcu-
lated underdosage of this portion of the PTV given the lack 
of soft tissue buildup.  This suggests that in using adaptive 
planning for targets that are on the surface, careful review of 
the planning contours to ensure there is appropriate mapping 
to the current surface is necessary.
The hybrid image based plan for the prostate cancer patient 
showed agreement to better than 1% for all parameters when 
compared to the kVCT plan (Fig. 1c).  Due to the nature of 
the region, this is to be expected: while the region is not of 
uniform density, only the femurs and portions of the rectum 
show large differences in atomic number and densities.  The 
majority of the contoured structures in the case of prostate 
cancer patients are large enough such that image noise, ar-
tifacts, and blurring are averaged and do not affect the plan 
in any significant manner.  With structures of similar density 
arranged in proximity, it is possible that the delineation of the 
structures on MVCT images may be more difficult (20).  De-
spite this concern, we noted high concordance between the 
PTV1 (prostate only) DVH between the kVCT and hybrid 
image plans suggesting contouring differences between the 
two studies was not an issue.  Likewise, good concordance 
between the rectal and bladder DVHs suggested minimal 
organ deformation between the kVCT and hybrid images. 
There was a noticeable difference between the verification 
dose and the planned dose for the PTV2 and seminal vesi-
cle structures as shown in Figure 1c.  The seminal vesicles 
are more mobile than the prostate and may be more subject 
to subtle changes in bladder and rectum volume leading to 
variation of dose deposition in the small (and hence more 
sensitive to tissue modification) volumes such as the seminal 
vesicle and PTV2 contours.  To account for this deformation, 
modification of the structures should be performed, although 
in this preliminary study we assumed that no modification 
to the structures occurs between time of kVCT and hybrid 
images on the first day of treatment.  Alternatively, repeating 
the comparison with kVCT and hybrid image done in closer 
temporal proximity (i.e., sequentially) may reduce this dis-
crepancy by reducing the possibility of changes in rectal and 
bladder filling between studies (21).
There was concern that breathing motion induced artifacts 
may lead to some errors in dose calculations in the case of the 
lung cancer patients (22); however, our data for this particu-
lar case did not show this.  In this case the tumor is attached 
to mediastunum and probably does not move much.  The re-
sults in Figure 1a and Table I may indicate that the motion 
induced artifacts, which could be different in the fast (gantry 
rotation speed of 0.5 s in kVCT) and slow (gantry rotation 
speed of 10 s in MVCT), or the blurring of motion, had not 
changed the dose distributions significantly.  If proved for a 
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larger cohort of lung cancer patients (or alternatively if the 
upper limit for tumor motion is defined), such insensitivity 
to motion artifacts could be very useful for adaptive radio-
therapy.  In some cases of lung cancer, the tumor will regress 
throughout treatment (12-14), allowing for further sparing 
of the ipsilateral lung, the contralateral lung, the heart, the 
spinal cord, and other OARs.  With less dose delivered to 
the OARs, complications, such as radiation pneumonitis and 
esophagitis, are less likely to occur, thus increasing the over-
all quality of life of the patients.
The minimum dose to the PTV for the nasal cavity cancer 
patient in Table III showed almost a 9% difference, while the 
remaining characteristics were below the 2% threshold.  The 
discrepancy is due to a portion of PTV in air (Fig. 3).
In the case of the brain cancer patient, there were significant 
differences in the dose calculations for lenses and the left op-
tic nerve, while the PTV, right optic nerve, and optic chiasm 
all showed excellent agreement.  Once again, with structures 
close to the surface a significant portion of both lenses are 
contoured outside of the patient and in air on the merged im-
age, causing the dose calculations for these structures located 
near the surface of the patient to be significantly different 
(Fig. 4).  In the case of the left optic nerve, the minimum dose 
may be affected by the blurring of the fine structures when 
using MVCT images with 6 mm slice spacing and interpola-
tion.  Quantifying the differences in the delineation of fine 
structures for head and neck cases in 6, 4, and 2 mm slice 
spacing would allow for the best choice in slice spacing to be 
made for adaptive planning purposes.  It may be that a policy 
of 6 mm scanning for daily localization with a repeat finer 
(2 or 4 mm scan) scan for adaptive planning (if concerning 
anatomy trends are noted on the routine localization scan-
ning) would be a good compromise between daily treatment 
efficiency and dose accuracy for adaptive re-planning.
Conclusions
In the case of the lung and prostate cancer patients, there is 
good agreement in the calculations of the verification doses 
and excellent agreement in the comparison of the hybrid im-
age based plans to the kVCT plans.  In these cases, the con-
toured structures are well within the patient; therefore there 
are no adverse effects due to surface dose calculations or 
patient deformation.  The structures in both these cases are 
also fairly large, allowing for image noise and poor contrast 
to be averaged out.  In both the nasal cavity and brain can-
cer patients, structures near the surface of the patient caused 
some discrepancies in dose calculations on the hybrid image 
plan due to small differences between the images.  Due to the 
decrease in quality of the MVCT image, fine anatomic struc-
tures are not as visible, and may cause some discrepancies in 
dose calculations.  Use of finer resolution MVCT scans for 
adaptive planning in these scenarios may be advisable.
Clinically, verification doses can be used to assess the dose 
delivered to patient over the course of treatment and are use-
ful in determining if anatomical changes are clinically rele-
vant.  This can be accomplished by adapting structures on the 
hybrid image to account for anatomy changes.  Since these 
patient images are already available, calculation of verifica-
tion doses offer an additional quality assurance option for 
patients treated on tomotherapy.  If the anatomical changes 
are clinically relevant, Planned Adaptive supplies tools with 
which adaptive plans can be created.  Future work will focus 
on verifying multi-fraction adaptive plans.  By using Planned 
Adaptive in conjunction with the planning station, more con-
formal radiation therapy may be possible, along with dose 
escalation, further sparing of critical structures, and conse-
quently, higher uncomplicated survival rates.
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